Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Significant Decrease in Short Interest

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a significant decline in short interest in February. As of February 28th, there was short interest totalling 38,900 shares, a decline of 68.0% from the February 13th total of 121,400 shares. Based on an average trading volume of 153,700 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.2% of the company’s stock are short sold.

Bolt Biotherapeutics Stock Down 4.9 %

BOLT stock opened at $0.40 on Thursday. Bolt Biotherapeutics has a fifty-two week low of $0.40 and a fifty-two week high of $1.56. The business’s 50-day moving average is $0.50 and its two-hundred day moving average is $0.57. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.16 and a current ratio of 3.16. The company has a market cap of $15.42 million, a price-to-earnings ratio of -0.24 and a beta of 0.94.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, November 13th. Five equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $3.50.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BOLT. FMR LLC lifted its holdings in Bolt Biotherapeutics by 33.2% in the third quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after acquiring an additional 28,773 shares during the period. Citadel Advisors LLC bought a new position in Bolt Biotherapeutics in the fourth quarter valued at about $42,000. Millennium Management LLC bought a new position in Bolt Biotherapeutics in the fourth quarter valued at about $25,000. Squarepoint Ops LLC bought a new position in shares of Bolt Biotherapeutics in the fourth quarter worth about $26,000. Finally, Velan Capital Investment Management LP bought a new position in shares of Bolt Biotherapeutics in the fourth quarter worth about $27,000. Institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.